Monument Therapeutics secures £850K to advance schizophrenia treatment with MT1988

25 Feb

Written By Alexandra Collingbourne

Alexandra Collingbourne

Sphere Fluidics rebrands to Sphere Bio

Healx doses first subject in Phase II neurofibromatosis type 1 therapy trial